India’s biggest drug company, Sun Pharmaceutical Industries Ltd, has bought the US company Organon & Co in an all-cash deal worth $11.75 billion.
This deal helps Sun Pharma grow bigger in the global market. After the acquisition, the company’s total revenue reaches about $12.4 billion, making it one of the top 25 pharmaceutical companies in the world.
With this move, Sun Pharma also becomes one of the top 3 companies globally in the women’s health sector, strengthening its position in the healthcare industry.
Dilip Shanghvi, Executive Chairman of Sun Pharma, said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own and we believe that bringing the two organizations together can create a stronger and more diversified platform. We have deep respect for Organon’s mission and look forward to building on its legacy while driving sustainable long‑term growth.”
This deal also helps Sun Pharma become one of the top 7 companies in biosimilars, which are cheaper versions of complex biotech medicines.
Organon is a global healthcare company that was formed in 2021 after it was separated from Merck (called MSD outside the US and Canada). It is well known and trusted by doctors, patients, and health regulators around the world.
The company mainly focuses on women’s health and sells more than 70 products, including medicines for women’s health, general treatments, and biosimilars. These products are available in over 140 countries, including major markets like the US, Europe, China, Canada, and Brazil.
Organon has six manufacturing plants in Europe and other developing regions, which helps it supply medicines globally. The company works to make healthcare more affordable and easier to access for people worldwide.
For the year ending December 31, 2025, Organon earned $6.2 billion in revenue and $1.9 billion in profit before certain costs (EBITDA). It also had $8.6 billion in debt and $574 million in cash. Recently, it sold one of its products and received $440 million, which will increase its cash in 2026.
Sun Pharma will buy all of Organon’s shares in a full cash deal. The purchase will be paid using existing money and bank loans. After the deal, Organon will become a part of Sun Pharma as its subsidiary.
Read More- Capital-A Raises INR 160 Crore in First Close of Fund II
